Teva Pharmaceutical (TEVA) Gets a Buy Rating from Raymond James
In a report released yesterday, Elliot Wilbur from Raymond James maintained a Buy rating on Teva Pharmaceutical (TEVA). The company’s shares closed last Friday at $11.12.
According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -0.3% and a 47.9% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Teva Pharmaceutical has an analyst consensus of Hold, with a price target consensus of $10.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.76 and a one-year low of $6.25. Currently, Teva Pharmaceutical has an average volume of 9.21M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.